Actively Recruiting
Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
Led by Capital Medical University · Updated on 2024-09-19
309
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial to evaluate the safety and efficacy of endovascular mechanical thrombectomy for acute basilar artery occlusion in the extended time window
CONDITIONS
Official Title
Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Posterior circulation acute ischemic stroke within 24-72 hours from symptom onset or last seen well, excluding isolated vertigo, with ineligibility or contraindication for IV thrombolytic treatment or no recanalization after IV thrombolysis
- Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries confirmed by imaging
- Age between 18 and 80 years
- Baseline NIH Stroke Scale score of 6 points or higher
- No significant disability before stroke (modified Rankin Scale 0-1)
- Treatable within 72 hours of symptom onset
- Informed consent obtained from patient or authorized surrogate
You will not qualify if you...
- Known bleeding disorders, coagulation factor deficiency, or oral anticoagulant therapy with INR greater than 3.0
- Baseline platelet count less than 50,000 per microliter
- Blood glucose below 50 mg/dL or above 400 mg/dL
- Severe sustained high blood pressure (systolic > 220 mm Hg or diastolic > 110 mm Hg) unless controlled
- Inability to obtain baseline NIH Stroke Scale score prior to sedation or intubation
- Seizures at stroke onset preventing baseline assessment
- Advanced or terminal illness with life expectancy under one year
- History of life-threatening allergy to contrast medium
- Acute stroke within 48 hours after major cardiac, cerebrovascular interventions, or surgery
- Renal insufficiency with creatinine level 3 mg/dL or higher
- Pregnant or lactating women
- Participation in another investigational drug or device study affecting this trial
- Known or suspected cerebral vasculitis
- Pre-existing neurological or psychiatric disease affecting evaluations
- Unlikely to be available for 90-day follow-up
- Other conditions posing significant risk as judged by the investigator
- Imaging evidence of severe brain infarcts, hemorrhage, or vascular issues preventing treatment access or safe device delivery
- Occlusions in both anterior and posterior circulation
- Presence of intracranial tumors except small meningiomas
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xuanwu hospital
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
Research Team
X
Xunming Ji
CONTACT
C
Chuanhui Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here